Aho, S., and Uitto, J. (1998). Direct interaction between the intracellular domains of
bullous pemphigoid antigen 2 (BP180) and beta 4 integrin, hemidesmosomal components
of basal keratinocytes. Biochem Bioph Res Co 243, 694–699.
Amano, S., Nishiyama, T., and Burgeson, R.E. (1999). A specific and sensitive ELISA
for laminin 5. J Immunol Methods 224, 161–169.
Amber, K.T., Murrell, D.F., Schmidt, E., Joly, P., and Borradori, L. (2018). Autoimmune
Subepidermal Bullous Diseases of the Skin and Mucosae: Clinical Features, Diagnosis,
and Management. Clin Rev Allerg Immu 54, 26–51.
Arai, M., Shirakawa, J., Konishi, H., Sagawa, N., and Terauchi, Y. (2018). Bullous
Pemphigoid and Dipeptidyl Peptidase 4 Inhibitors: A Disproportionality Analysis Based
on the Japanese Adverse Drug Event Report Database. Diabetes Care 41, e130–e132.
Balding, S.D., Prost, C., Diaz, L.A., Bernard, P., Bedane, C., Aberdam, D., and Giudice,
G.J. (1996). Cicatricial Pemphigoid Autoantibodies React with Multiple Sites on the
BP180 Extracellular Domain. J Invest Dermatol 106, 141–146.
Béné, J., Moulis, G., Bennani, I., Auffret, M., Coupe, P., Babai, S., Hillaire‐Buys, D.,
Micallef, J., Gautier, S., and Centres, the F.A. of R.P. (2016). Bullous pemphigoid and
dipeptidyl peptidase IV inhibitors: a case–noncase study in the French Pharmacovigilance
Database. Br J Dermatol 175, 296–301.
Boukamp, P., Petrussevska, R.T., Breitkreutz, D., Hornung, J., Markham, A., and Fusenig,
N.E. (1988). Normal keratinization in a spontaneously immortalized aneuploid human
keratinocyte cell line. J Cell Biology 106, 761–771.
Chan, L.S., Soong, H.K., Foster, C.S., Hammerberg, C., and Cooper, K.D. (1991). Ocular
Cicatricial Pemphigoid Occurring as a Sequela of Stevens-Johnson Syndrome. Jama 266,
1543–1546.
Chan, L.S., Majmudar, A.A., Tran, H.H., Meier, F., Schaumburg-Lever, G., Chen, M.,
Anhalt, G., Woodley, D.T., and Marinkovich, M.P. (1997). Laminin-6 and laminin-5 are
56
recognized by autoantibodies in a subset of cicatricial pemphigoid. J Invest Dermatol 108,
848–853.
Chan, L.S., Vanderlugt, C.J., Hashimoto, T., Nishikawa, T., Zone, J.J., Black, M.M.,
Wojnarowska, F., Stevens, S.R., Chen, M., Fairley, J.A., et al. (1998). Epitope Spreading:
Lessons From Autoimmune Skin Diseases. J Invest Dermatol 110, 103–109.
Chan, L.S., Ahmed, A.R., Anhalt, G.J., Bernauer, W., Cooper, K.D., Elder, M.J., Fine,
J.-D., Foster, C.S., Ghohestani, R., Hashimoto, T., et al. (2002). The first international
consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic
factors, medical treatment, and prognostic indicators. Arch Dermatol 138, 370–379.
Chan, R.Y., Bhol, K., Tesavibul, N., Letko, E., Simmons, R.K., Foster, C.S., and Ahmed,
A.R. (1999). The role of antibody to human beta4 integrin in conjunctival basement
membrane separation: possible in vitro model for ocular cicatricial pemphigoid. Invest
Ophth Vis Sci 40, 2283–2290.
Condrat, I., He, Y., Cosgarea, R., and Has, C. (2019). Junctional Epidermolysis Bullosa:
Allelic Heterogeneity and Mutation Stratification for Precision Medicine. Frontiers
Medicine 5, 363.
Cozzani, E., Di Zenzo, G., Calabresi, V., Carrozzo, M., Burlando, M., Longanesi, L.,
Cerri, A., Caproni, M., Sera, F., Antiga, E., et al. (2014). Autoantibody Profile of a Cohort
of 78 Italian Patients with Mucous Membrane Pemphigoid: Correlation Between
Reactivity Profile and Clinical Involvement. Acta Dermato Venereol 96, 768–773.
Diaz, L.A., Ratrie, H., Saunders, W.S., Futamura, S., Squiquera, H.L., Anhalt, G.J., and
Giudice, G.J. (1990). Isolation of a human epidermal cDNA corresponding to the 180kD autoantigen recognized by bullous pemphigoid and herpes gestationis sera.
Immunolocalization of this protein to the hemidesmosome. J Clin Invest 86, 1088–1094.
Didona, D., and Di Zenzo, G. (2018). Humoral Epitope Spreading in Autoimmune
Bullous Diseases. Front Immunol 9, 779.
Doyle, H.A., and Mamula, M.J. (2002). Posttranslational protein modifications: new
flavors in the menu of autoantigens. Current Opinion in Rheumatology 14, 244–249.
57
Du, G., Patzelt, S., Beek, N. van, and Schmidt, E. (2022). Mucous membrane pemphigoid.
Autoimmun Rev 21, 103036.
Egami, S., Yamagami, J., and Amagai, M. (2020). Autoimmune bullous skin diseases,
pemphigus and pemphigoid. J Allergy Clin Immun 145, 1031–1047.
Franzke, C., Tasanen, K., Schäcke, H., Zhou, Z., Tryggvason, K., Mauch, C., Zigrino, P.,
Sunnarborg, S., Lee, D.C., Fahrenholz, F., et al. (2002). Transmembrane collagen XVII,
an epithelial adhesion protein, is shed from the cell surface by ADAMs. EMBO J 21,
5026–5035.
Franzke, C.-W., Tasanen, K., Schumann, H., and Bruckner-Tuderman, L. (2003).
Collagenous transmembrane proteins: collagen XVII as a prototype. Matrix Biol 22, 299–
309.
Franzke, C.-W., Bruckner, P., and Bruckner-Tuderman, L. (2005). Collagenous
Transmembrane Proteins: Recent Insights into Biology and Pathology. J Biol Chem 280,
4005–4008.
Gammon, W.R., Briggaman, R.A., Inman, A.O., Queen, L.L., and Wheeler, C.E. (1984).
Differentiating Anti-Lamina Lucida and Anti-Sublamina Densa Anti-BMZ Antibodies
by Indirect Immunofluorescence on 1.0 M Sodium Chloride-Separated Skin. J Invest
Dermatol 82, 139–144.
Ghohestani, R.F., Nicolas, J.F., Rousselle, P., and Claudy, A.L. (1996). Identification of
A 168-kDa Mucosal Antigen In A Subset of Patients With Cicatricial Pemphigoid. J
Invest Dermatol 107, 136–139.
Giudice, G.J., Emery, D.J., and Diaz, L.A. (1992). Cloning and Primary Structural
Analysis of the Bullous Pemphigoid Autoantigen BP180. J Invest Dermatol 99, 243–250.
Giudice, G.J., Emery, D.J., Zelickson, B.D., Anhalt, G.J., Liu, Z., and Diaz, L.A. (1993).
Bullous pemphigoid and herpes gestationis autoantibodies recognize a common noncollagenous site on the BP180 ectodomain. J Immunol Baltim Md 1950 151, 5742–5750.
Hamill, K.J., Hopkinson, S.B., Jonkman, M.F., and Jones, J.C.R. (2011). Type XVII
Collagen Regulates Lamellipod Stability, Cell Motility, and Signaling to Rac1 by
58
Targeting Bullous Pemphigoid Antigen 1e to α6β4 Integrin. J Biol Chem 286, 26768–
26780.
Has, C., Bauer, J.W., Bodemer, C., Bolling, M.C., Bruckner‐Tuderman, L., Diem, A.,
Fine, J. ‐D., Heagerty, A., Hovnanian, A., Marinkovich, M.P., et al. (2020). Consensus
reclassification of inherited epidermolysis bullosa and other disorders with skin fragility.
Br J Dermatol 183, 614–627.
Hayakawa, T., Furumura, M., Fukano, H., Li, X., Ishii, N., Hamada, T., Ohata, C.,
Tsuruta, D., Shimozato, K., and Hashimoto, T. (2014). Diagnosis of oral mucous
membrane pemphigoid by means of combined serologic testing. Oral Surg Oral Medicine
Oral Pathology Oral Radiology 117, 483–496.
Hirako, Y., Usukura, J., Nishizawa, Y., and Owaribe, K. (1996). Demonstration of the
Molecular Shape of BP180, a 180-kDa Bullous Pemphigoid Antigen and Its Potential for
Trimer Formation. J Biol Chem 271, 13739–13745.
Hirako, Y., Yonemoto, Y., Yamauchi, T., Nishizawa, Y., Kawamoto, Y., and Owaribe,
K. (2014). Isolation of a hemidesmosome-rich fraction from a human squamous cell
carcinoma cell line. Exp Cell Res 324, 172–182.
Hofmann, S.C., Thoma-Uszynski, S., Stauber, A., Schuler, G., Hertl, M., Hunziker, T.,
Bernard, P., Koebnick, C., and Borradori, L. (2002). Severity and Phenotype of Bullous
Pemphigoid Relate to Autoantibody Profile Against the NH2- and COOH-Terminal
Regions of the BP180 Ectodomain. J Invest Dermatol 119, 1065–1073.
Hofmann, S.C., Voith, U., Schönau, V., Sorokin, L., Bruckner-Tuderman, L., and
Franzke, C.-W. (2009). Plasmin Plays a Role in the In Vitro Generation of the Linear IgA
Dermatosis Antigen LADB97. J Invest Dermatol 129, 1730–1739.
Hopkinson, S.B., and Jones, J.C.R. (2000). The N Terminus of the Transmembrane
Protein BP180 Interacts with the N-terminal Domain of BP230, Thereby Mediating
Keratin Cytoskeleton Anchorage to the Cell Surface at the Site of the Hemidesmosome.
Mol Biol Cell 11, 277–286.
Hopkinson, S.B., Baker, S.E., and Jones, J.C. (1995). Molecular genetic studies of a
human epidermal autoantigen (the 180-kD bullous pemphigoid antigen/BP180):
identification of functionally important sequences within the BP180 molecule and
59
evidence for an interaction between BP180 and alpha 6 integrin. J Cell Biology 130, 117–
125.
Horikawa, H., Kurihara, Y., Funakoshi, T., Umegaki‐Arao, N., Takahashi, H., Kubo, A.,
Tanikawa, A., Kodani, N., Minami, Y., Meguro, S., et al. (2018). Unique clinical and
serological features of bullous pemphigoid associated with dipeptidyl peptidase‐4
inhibitors. Br J Dermatol 178, 1462–1463.
Inoue, T., Yagami, A., Iwata, Y., Ishii, N., Hashimoto, T., and Matsunaga, K. (2016).
Mucous membrane pemphigoid reactive only with BP230. J Dermatology 43, 1228–1229.
Ishiko, A., Shimizu, H., Kikuchi, A., Ebihara, T., Hashimoto, T., and Nishikawa, T.
(1993). Human autoantibodies against the 230-kD bullous pemphigoid antigen (BPAG1)
bind only to the intracellular domain of the hemidesmosome, whereas those against the
180-kD bullous pemphigoid antigen (BPAG2) bind along the plasma membrane of the
hemidesmosome in normal human and swine skin. J Clin Invest 91, 1608–1615.
Izumi, K., Nishie, W., Mai, Y., Wada, M., Natsuga, K., Ujiie, H., Iwata, H., Yamagami,
J., and Shimizu, H. (2016). Autoantibody Profile Differentiates between Inflammatory
and Noninflammatory Bullous Pemphigoid. J Invest Dermatol 136, 2201–2210.
Izumi, K., Nishie, W., Mai, Y., Ujiie, H., Iwata, H., Natsuga, K., and Shimizu, H. (2017).
Detection of mucous membrane pemphigoid autoantibodies by full-length BP180
enzyme-linked immunosorbent assay. J Dermatol Sci 88, 247–248.
Kamaguchi, M., and Iwata, H. (2019). The Diagnosis and Blistering Mechanisms of
Mucous Membrane Pemphigoid. Front Immunol 10, 34.
Kershenovich, R., Hodak, E., and Mimouni, D. (2014). Diagnosis and classification of
pemphigus and bullous pemphigoid. Autoimmun Rev 13, 477–481.
Kobayashi, M., Amagai, M., Kuroda-Kinoshita, K., Hashimoto, T., Shirakata, Y.,
Hashimoto, K., and Nishikawa, T. (2002). BP180 ELISA using bacterial recombinant
NC16a protein as a diagnostic and monitoring tool for bullous pemphigoid. J Dermatol
Sci 30, 224–232.
60
Koster, J., Geerts, D., Favre, B., Borradori, L., and Sonnenberg, A. (2003). Analysis of
the interactions between BP180, BP230, plectin and the integrin α6β4 important for
hemidesmosome assembly. J Cell Sci 116, 387–399.
Kridin, K., and Bergman, R. (2018). Association of Bullous Pemphigoid With
Dipeptidyl-Peptidase 4 Inhibitors in Patients With Diabetes: Estimating the Risk of the
New Agents and Characterizing the Patients. Jama Dermatol 154, 1152.
Kridin, K., and Cohen, A.D. (2018). Dipeptidyl-peptidase IV inhibitor-associated bullous
pemphigoid: A systematic review and meta-analysis. J Am Acad Dermatol 85, 501–503.
Labib, R.S., Anhalt, G.J., Patel, H.P., Mutasim, D.F., and Diaz, L.A. (1986). Molecular
heterogeneity of the bullous pemphigoid antigens as detected by immunoblotting. J
Immunol Baltim Md 1950 136, 1231–1235.
Lackner, D.H., Carré, A., Guzzardo, P.M., Banning, C., Mangena, R., Henley, T.,
Oberndorfer, S., Gapp, B.V., Nijman, S.M.B., Brummelkamp, T.R., et al. (2015). A
generic strategy for CRISPR-Cas9-mediated gene tagging. Nat Commun 6, 10237.
Leverkus, M., Bhol, K., Hirako, Y., Pas, H., Sitaru, C., Baier, G., Bröcker, E., Jonkman,
M.F., Ahmed, A.R., and Zillikens, D. (2001). Cicatricial pemphigoid with circulating
autoantibodies to β4 integrin, bullous pemphigoid 180 and bullous pemphigoid 230. Br J
Dermatol 145, 998–1004.
Mai, Y., Nishie, W., Izumi, K., Yoshimoto, N., Morita, Y., Watanabe, M., Toyonaga, E.,
Ujiie, H., Iwata, H., Fujita, Y., et al. (2018). Detection of anti‐BP180 NC16A
autoantibodies after the onset of dipeptidyl peptidase‐IV inhibitor‐associated bullous
pemphigoid: a report of three patients. Br J Dermatol 179, 790–791.
Mai, Y., Ujiie, H., Higashi, T., Yamagami, J., Iwata, H., and Shimizu, H. (2019).
Autoantibodies undetectable by chemiluminescent enzyme immunoassay require
extended antigen–antibody reaction time for detection. Br J Dermatol 180, 215–216.
Matsumura, K., Amagai, M., Nishikawa, T., and Hashimoto, T. (1996). The majority of
bullous pemphigoid and herpes gestationis serum samples react with the NC16a domain
of the 180-kDa bullous pemphigoid antigen. Arch Dermatol Res 288, 507–509.
61
McMillan, J.R., Akiyama, M., and Shimizu, H. (2003). Epidermal basement membrane
zone components: ultrastructural distribution and molecular interactions. J Dermatol Sci
31, 169–177.
Murrell, D.F., Daniel, B.S., Joly, P., Borradori, L., Amagai, M., Hashimoto, T., Caux, F.,
Marinovic, B., Sinha, A.A., Hertl, M., et al. (2012). Definitions and outcome measures
for bullous pemphigoid: Recommendations by an international panel of experts. J Am
Acad Dermatol 66, 479–485.
Natsuga, K., Nishie, W., Shinkuma, S., Ujiie, H., Nishimura, M., Sawamura, D., and
Shimizu, H. (2012). Antibodies to Pathogenic Epitopes on Type XVII Collagen Cause
Skin Fragility in a Complement-Dependent and -Independent Manner. J Immunol 188,
5792–5799.
Natsuga, K., Nishie, W., Nishimura, M., Shinkuma, S., Watanabe, M., Izumi, K.,
Nakamura, H., Hirako, Y., and Shimizu, H. (2017). Loss of interaction between plectin
and type XVII collagen results in epidermolysis bullosa simplex. Hum Mutat 38, 1666–
1670.
Nishie, W. (2014). Update on the pathogenesis of bullous pemphigoid: An autoantibodymediated blistering disease targeting collagen XVII. J Dermatol Sci 73, 179–186.
Nishie, W., Sawamura, D., Goto, M., Ito, K., Shibaki, A., McMillan, J.R., Sakai, K.,
Nakamura, H., Olasz, E., Yancey, K.B., et al. (2007). Humanization of autoantigen. Nat
Med 13, 378–383.
Nishie, W., Lamer, S., Schlosser, A., Licarete, E., Franzke, C.-W., Hofmann, S.C.,
Jackow, J., Sitaru, C., and Bruckner-Tuderman, L. (2010). Ectodomain Shedding
Generates Neoepitopes on Collagen XVII, the Major Autoantigen for Bullous
Pemphigoid. J Immunol 185, 4938–4947.
Nishie, W., Kiritsi, D., Nyström, A., Hofmann, S.C., and Bruckner-Tuderman, L. (2011).
Dynamic Interactions of Epidermal Collagen XVII with the Extracellular Matrix Laminin
332 as a Major Binding Partner. Am J Pathology 179, 829–837.
Nishimura, M., Nishie, W., Shirafuji, Y., Shinkuma, S., Natsuga, K., Nakamura, H.,
Sawamura, D., Iwatsuki, K., and Shimizu, H. (2016). Extracellular cleavage of collagen
62
XVII is essential for correct cutaneous basement membrane formation. Hum Mol Genet
25, 328–339.
Nonaka, S., Ishiko, A., Masunaga, T., Nishikawa, T., Akiyama, M., Owaribe, K., and
Shimizu, H. (2000). The Extracellular Domain of BPAG2 has a Loop Structure in the
Carboxy Terminal Flexible Tail In Vivo. J Invest Dermatol 115, 889–892.
Owaribe, K., Nishizawa, Y., and Franke, W.W. (1991). Isolation and characterization of
hemidesmosomes from bovine corneal epithelial cells. Exp Cell Res 192, 622–630.
Oyama, N., Setterfield, J.F., Powell, A.M., Sakuma‐Oyama, Y., Albert, S., Bhogal, B.S.,
Vaughan, R.W., Kaneko, F., Challacombe, S.J., and Black, M.M. (2006). Bullous
pemphigoid antigen II (BP180) and its soluble extracellular domains are major
autoantigens in mucous membrane pemphigoid: the pathogenic relevance to HLA class
II alleles and disease severity. Br J Dermatol 154, 90–98.
Qian, H., Natsuaki, Y., Koga, H., Kawakami, T., Tateishi, C., Tsuruta, D., Ishii, N., Li,
X., and Hashimoto, T. (2021). The Second Study of Clinical and Immunological Findings
in Anti-laminin 332-Type Mucous Membrane Pemphigoid Examined at Kurume
University—Diagnosis Criteria Suggested by Summary of 133 Cases. Front Immunol 12,
771766.
Rashid, K.A., Gürcan, H.M., and Ahmed, A.R. (2006a). Antigen Specificity in Subsets
of Mucous Membrane Pemphigoid. J Invest Dermatol 126, 2631–2636.
Rashid, K.A., Stern, J.N.H., and Ahmed, A.R. (2006b). Identification of an Epitope
within Human Integrin α6 Subunit for the Binding of Autoantibody and Its Role in
Basement Membrane Separation in Oral Pemphigoid. J Immunol 176, 1968–1977.
Schaapveld, R.Q.J., Borradori, L., Geerts, D., Leusden, M.R. van, Kuikman, I., Nievers,
M.G., Niessen, C.M., Steenbergen, R.D.M., Snijders, P.J.F., and Sonnenberg, A. (1998).
Hemidesmosome Formation Is Initiated by the β4 Integrin Subunit, Requires Complex
Formation of β4 and HD1/Plectin, and Involves a Direct Interaction between β4 and the
Bullous Pemphigoid Antigen 180. J Cell Biology 142, 271–284.
Schmidt, E., and Zillikens, D. (2013). Pemphigoid diseases. Lancet 381, 320--332.
63
Schmidt, E., Skrobek, C., Kromminga, A., Hashimoto, T., Messer, G., Bröcker, E.,
Yancey, K.B., and Zillikens, D. (2001). Cicatricial pemphigoid: IgA and IgG
autoantibodies target epitopes on both intra‐ and extracellular domains of bullous
pemphigoid antigen 180. Br J Dermatol 145, 778–783.
Schmitt, J., and Papisch, W. (2002). Recombinant autoantigens. Autoimmun Rev 1, 79–
88.
Skandalis, K., Spirova, M., Gaitanis, G., Tsartsarakis, A., and Bassukas, I.D. (2012).
Drug‐induced bullous pemphigoid in diabetes mellitus patients receiving dipeptidyl
peptidase‐IV inhibitors plus metformin. J Eur Acad Dermatol 26, 249–253.
Smith, E.P., Taylor, T.B., Meyer, L.J., and Zone, J.J. (1993). Identification of a Basement
Membrane Zone Antigen Reactive with Circulating IgA Antibody in Ocular Cicatricial
Pemphigoid. J Invest Dermatol 101, 619–623.
Ständer, S., Schmidt, E., Zillikens, D., Ludwig, R.J., and Kridin, K. (2021). More Severe
Erosive Phenotype Despite Lower Circulating Autoantibody Levels in Dipeptidyl
Peptidase-4 Inhibitor (DPP4i)-Associated Bullous Pemphigoid: A Retrospective Cohort
Study. Am J Clin Dermatol 22, 117–127.
Tasanen, K., Tunggal, L., Chometon, G., Bruckner-Tuderman, L., and Aumailley, M.
(2004). Keratinocytes from Patients Lacking Collagen XVII Display a Migratory
Phenotype. Am J Pathology 164, 2027–2038.
Tasanen, K., Varpuluoma, O., and Nishie, W. (2019). Dipeptidyl Peptidase-4 InhibitorAssociated Bullous Pemphigoid. Front Immunol 10, 1238.
Toyonaga, E., Nishie, W., Izumi, K., Natsuga, K., Ujiie, H., Iwata, H., Yamagami, J.,
Hirako, Y., Sawamura, D., Fujimoto, W., et al. (2017). C-Terminal Processing of
Collagen XVII Induces Neoepitopes for Linear IgA Dermatosis Autoantibodies. J Invest
Dermatol 137, 2552--2559.
Tsunenaga, M., Adachi, E., Amano, S., Burgeson, R.E., and Nishiyama, T. (1998).
Laminin 5 can promote assembly of the lamina densa in the skin equivalent model. Matrix
Biol 17, 603–613.
64
Ujiie, H., Muramatsu, K., Mushiroda, T., Ozeki, T., Miyoshi, H., Iwata, H., Nakamura,
A., Nomoto, H., Cho, K.Y., Sato, N., et al. (2018). HLA-DQB1*03:01 as a Biomarker
for Genetic Susceptibility to Bullous Pemphigoid Induced by DPP-4 Inhibitors. J Invest
Dermatol 138, 1201–1204.
Ujiie, H., Iwata, H., Yamagami, J., Nakama, T., Aoyama, Y., Ikeda, S., Ishii, N., Iwatsuki,
K., Kurosawa, M., Sawamura, D., et al. (2019a). Japanese guidelines for the management
of pemphigoid (including epidermolysis bullosa acquisita). J Dermatology 46, 1102–
1135.
Ujiie, H., Yoshimoto, N., Natsuga, K., Muramatsu, K., Iwata, H., Nishie, W., and Shimizu,
H. (2019b). Immune Reaction to Type XVII Collagen Induces Intramolecular and
Intermolecular Epitope Spreading in Experimental Bullous Pemphigoid Models. Front
Immunol 10, 1410.
Varpuluoma, O., Försti, A.-K., Jokelainen, J., Turpeinen, M., Timonen, M., Huilaja, L.,
and Tasanen, K. (2018). Vildagliptin significantly increases the risk of bullous
pemphigoid: A Finnish nationwide registry study. J Invest Dermatol 138, 1659–1661.
Yasukochi, A., Teye, K., Ishii, N., and Hashimoto, T. (2016). Clinical and Immunological
Studies of 332 Japanese Patients Tentatively Diagnosed as Anti-BP180-type Mucous
Membrane Pemphigoid: A Novel BP180 C-terminal Domain Enzyme-linked
Immunosorbent Assay. Acta Dermato Venereol 96, 762–767.
Yeh, S.W., Usman, A.Q., and Ahmed, A.R. (2004). Profile of autoantibody to basement
membrane zone proteins in patients with mucous membrane pemphigoid: long-term
follow up and influence of therapy. Clin Immunol 112, 268–272.
Di Zenzo, G., Thoma-Uszynski, S., Calabresi, V., Fontao, L., Hofmann, S.C., Lacour, J.P., Sera, F., Bruckner-Tuderman, L., Zambruno, G., Borradori, L., et al. (2011).
Demonstration of Epitope-Spreading Phenomena in Bullous Pemphigoid: Results of a
Prospective Multicenter Study. J Invest Dermatol 131, 2271–2280.
65
...
論文の公開元へ
